Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo.

Autor: Dubiella C; Department of Organic Chemistry, The Weizmann Institute of Science, Rehovot, Israel., Pinch BJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.; Department of Chemistry and Chemical Biology, Department of Chemical Biology, Harvard University, Cambridge, MA, USA., Koikawa K; Department of Medicine, Division of Translational Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Zaidman D; Department of Organic Chemistry, The Weizmann Institute of Science, Rehovot, Israel., Poon E; Division of Clinical Studies, The Institute of Cancer Research, London, UK., Manz TD; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.; Department of Pharmaceutical and Medicinal Chemistry, Saarland University, Saarbruecken, Germany., Nabet B; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., He S; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Resnick E; Department of Organic Chemistry, The Weizmann Institute of Science, Rehovot, Israel., Rogel A; Department of Organic Chemistry, The Weizmann Institute of Science, Rehovot, Israel., Langer EM; Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR, USA.; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Daniel CJ; Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR, USA.; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Seo HS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Chen Y; College of Chemistry and Molecular Engineering, Peking University, Beijing, China., Adelmant G; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Blais Proteomics Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Sharifzadeh S; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Blais Proteomics Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Ficarro SB; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Blais Proteomics Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Jamin Y; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK., Martins da Costa B; Division of Clinical Studies, The Institute of Cancer Research, London, UK., Zimmerman MW; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Lian X; Department of Medicine, Division of Translational Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Kibe S; Department of Medicine, Division of Translational Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Kozono S; Department of Medicine, Division of Translational Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Doctor ZM; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Browne CM; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.; Discovery Biology, Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Boston, MA, USA., Yang A; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Stoler-Barak L; Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel., Shah RB; Department of Medicine, Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Department of Cell, Developmental and Regenerative Biology, The Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Vangos NE; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Geffken EA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Oren R; Department of Veterinary Resources, The Weizmann Institute of Science, Rehovot, Israel., Koide E; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Sidi S; Department of Medicine, Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Department of Cell, Developmental and Regenerative Biology, The Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Shulman Z; Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel., Wang C; College of Chemistry and Molecular Engineering, Peking University, Beijing, China., Marto JA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Blais Proteomics Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Dhe-Paganon S; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Look T; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Division of Pediatric Hematology/Oncology Boston Children's Hospital, Boston, MA, USA., Zhou XZ; Department of Medicine, Division of Translational Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Lu KP; Department of Medicine, Division of Translational Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Sears RC; Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR, USA.; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.; Brenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, OR, USA., Chesler L; Division of Clinical Studies, The Institute of Cancer Research, London, UK., Gray NS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. nsgray01@stanford.edu.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. nsgray01@stanford.edu.; Department of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, CA, USA. nsgray01@stanford.edu., London N; Department of Organic Chemistry, The Weizmann Institute of Science, Rehovot, Israel. nir.london@weizmann.ac.il.

Publikováno v: Nature chemical biology [Nat Chem Biol] 2021 Sep; Vol. 17 (9), pp. 954-963. Date of Electronic Publication: 2021 May 10.

Impact of stroma remodeling on forces experienced by cancer cells and stromal cells within a pancreatic tumor tissue.

Autor: Connaughton, Morgan¹ (AUTHOR), Dabagh, Mahsa¹ (AUTHOR) dabaghme@uwm.edu

Publikováno v: BioMedical Engineering OnLine. 8/30/2024, p1-19. 19p.

Current and future immunotherapeutic approaches in pancreatic cancer treatment.

Autor: Farhangnia, Pooya^1,2,3,4 (AUTHOR), Khorramdelazad, Hossein⁵ (AUTHOR), Nickho, Hamid^2,3 (AUTHOR), Delbandi, Ali-Akbar^1,2,3 (AUTHOR) Delbandi.ak@Iums.ac.ir

Publikováno v: Journal of Hematology & Oncology. 6/4/2024, Vol. 17 Issue 1, p1-66. 66p.

Pin1-Catalyzed Conformation Changes Regulate Protein Ubiquitination and Degradation.

Autor: Jeong, Jessica^1,2 (AUTHOR) jjeong63@uwo.ca, Usman, Muhammad^1,2 (AUTHOR), Li, Yitong^1,2 (AUTHOR), Zhou, Xiao Zhen^1,3,4 (AUTHOR) xzhou659@uwo.ca, Lu, Kun Ping^1,2 (AUTHOR) xzhou659@uwo.ca

Publikováno v: Cells (2073-4409). May2024, Vol. 13 Issue 9, p731. 27p.

Structural Elucidation of a Nonpeptidic Inhibitor Specific for the Human Immunoproteasome.

Autor: Cui H; Center for Integrated Protein Science Munich (CIPSM), Department of Chemistry, Technische Universität München, Lichtenbergstrasse 4, 85748, Garching, Germany., Baur R; Center for Integrated Protein Science Munich (CIPSM), Department of Chemistry, Technische Universität München, Lichtenbergstrasse 4, 85748, Garching, Germany., Le Chapelain C; Center for Integrated Protein Science Munich (CIPSM), Department of Chemistry, Technische Universität München, Lichtenbergstrasse 4, 85748, Garching, Germany., Dubiella C; Center for Integrated Protein Science Munich (CIPSM), Department of Chemistry, Technische Universität München, Lichtenbergstrasse 4, 85748, Garching, Germany., Heinemeyer W; Center for Integrated Protein Science Munich (CIPSM), Department of Chemistry, Technische Universität München, Lichtenbergstrasse 4, 85748, Garching, Germany., Huber EM; Center for Integrated Protein Science Munich (CIPSM), Department of Chemistry, Technische Universität München, Lichtenbergstrasse 4, 85748, Garching, Germany., Groll M; Center for Integrated Protein Science Munich (CIPSM), Department of Chemistry, Technische Universität München, Lichtenbergstrasse 4, 85748, Garching, Germany.

Publikováno v: Chembiochem : a European journal of chemical biology [Chembiochem] 2017 Mar 16; Vol. 18 (6), pp. 523-526. Date of Electronic Publication: 2017 Feb 22.